We have successfully completed numerous studies, helping to explore the safety and effectiveness of new vaccines and therapeutics.

Explore our research discoveries for summaries of our most impactful study results or view our enrolling studies to learn more about how you can participate in a clinical study with us.

Influenza (Flu) Studies

A Phase 1 Placebo-Controlled Randomized Observer-Blind Dose-Finding Study to Evaluate the Safety Tolerability and Immunogenicity of Self-Amplifying RNA Vaccine Preparations Against Influenza in Healthy Individuals

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA (mRNA) Vaccine Against Influenza

A Study to Evaluate the Safety, Tolerability, Efficacy, and Immunogenicity of Self-Amplifying RNA Vaccine Preparations Against Influenza in Healthy Individuals

COVID-19 Studies

MixNMatch COVID Booster Study - A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) after Receipt of EUA Vaccines (NIH/DMID)

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial, NIAID)

Study to Optimize Immune Coverage of SARS-CoV-2 Existing and Emerging Variants COVAIL Booster Study

Multisite Observational Maternal and Infant Study for COVID-19 (MomiVax Study, NIAID). Immune Response and Safety of COVID-19 Vaccines Administered to Pregnant and Postpartum People and Evaluation of Antibody Transfer to Infants

Phase 3 Double-Blind, Placebo-Controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

Phase 1/2 Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults

Study of Recombinant Protein Vaccines with Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older

Evaluating the Safety, Tolerability, Efficacy, and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants at Least 12 Years of Age

Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2

A Multicenter, Adaptive, Randomized, Blinded, Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT4)

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies for Prevention of SARS-CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual with a Positive SARS-CoV-2 RT-PCR Assay

A Randomized Placebo-Controlled, Double-Blind Sponsor Unblinded Single Ascending Dose Phase 1 First in Human Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19

A Study of SARS-CoV-2 Infection and Potential Transmission in Individuals Immunized with Moderna COVID-19 Vaccine

Clostridium Difficile Infection Studies

Randomized Phase 2 Study of VE303 for Prevention of Recurrent Clostridium Difficile Infection (CONSORTIUM)